The service uses CMDX's Constitutional Genetic Array Test, which can genetically identify more than 50 "common" genetic disorders, including developmental disorders. The service is already sold in
CMDX said it's in the "final phases" of internal human and clinical validation.
In March, CMDX and Array Genomics said they plan to co-develop and co-market a series of comparative genomic hybridization microarrays for diagnosing genetic anomalies associated with mental retardation, a developmental disorder.
Matt Watson, CEO of CMDX, said the subsidiary is "actively developing further tests based on both our oligo- and BAC capabilities that augment our microarray portfolio and over the next three quarters, we have plans to launch three to five additional products into the molecular diagnostics market."